These reports support the contention that oleamide, which is an agonist of CB2, suppresses the microglial inflammation and enhances the phagocytosis of Aβ, resulting in a preventive action against Alzheimer’s disease. Here, CNR2 is linked to early-onset autosomal dominant Alzheimer disease.